Hims & Hers Health (NYSE:HIMS) Given New $20.00 Price Target at Bank of America

Hims & Hers Health (NYSE:HIMSFree Report) had its price objective lowered by Bank of America from $24.00 to $20.00 in a report published on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. TD Cowen raised their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a buy rating in a report on Thursday, July 11th. Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a hold rating in a report on Thursday, July 18th. Imperial Capital cut shares of Hims & Hers Health from an outperform rating to an in-line rating in a research note on Friday, August 9th. Piper Sandler reiterated a neutral rating and issued a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Finally, Citigroup lowered shares of Hims & Hers Health from a buy rating to a neutral rating and boosted their target price for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of Moderate Buy and an average target price of $19.86.

View Our Latest Stock Report on Hims & Hers Health

Hims & Hers Health Stock Up 4.7 %

Shares of NYSE:HIMS opened at $16.57 on Friday. The firm has a fifty day moving average of $17.80 and a two-hundred day moving average of $16.95. The firm has a market capitalization of $3.56 billion, a P/E ratio of -1,657.00 and a beta of 1.05. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $25.74.

Hims & Hers Health (NYSE:HIMSGet Free Report) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) EPS. Equities research analysts expect that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $22.07, for a total transaction of $381,877.21. Following the completion of the transaction, the insider now directly owns 185,326 shares in the company, valued at $4,090,144.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The disclosure for this sale can be found here. Insiders have sold a total of 753,292 shares of company stock valued at $13,557,329 over the last three months. 17.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Hims & Hers Health by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after buying an additional 193,507 shares in the last quarter. Farallon Capital Management LLC increased its position in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Hims & Hers Health by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after acquiring an additional 22,009 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Recommended Stories

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.